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Cyclosporin A (CsA) is effective at reducing pathogenic immune responses, but upon withdrawal of CsA
the immune response often “rebounds” resulting in a relapse or exacerbation of disease. The mechanisms,
cells and cytokines involved in the relapse or exacerbation after CsA withdrawal are unknown. We hy-
pothesized that CsA withdrawal induces IL-17 production that could be responsible for relapse, and
examined the effect of anti-IL-17A antibody on relapse induced after CsA withdrawal in mouse experi-
mental autoimmune encephalomyelitis (EAE). CsA treatment markedly decreased the EAE disease score
during the ﬁrst episode, but augmented disease severity after CsA withdrawal, compared to untreated
mice. After discontinuation of CsA the production of IL-17A was increased and the severity of relapse in
EAE was reduced by treatment with anti-IL-17A antibody. These results suggest that the resumption of T
cell immune responses after CsA withdrawal leads to a burst of IL-17A production that is at least partially
responsible for relapse in EAE mice.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cyclosporin A (CsA) is an immunosuppressant drug that com-
bines with cyclophilin inside cells to form an inhibitor of calci-
neurin, a key signalling molecule in the nuclear factor of activated
T cells (NFATc) transcription activator pathway. Inhibiting calci-
neurin and preventing the activation of NFATc leads to a reduction
in the production of growth factors and proinﬂammatory cyto-
kines secreted by T cells, and dampens immune responses and
inﬂammation [1,2]. The immunosuppressive effects of CsA are
particularly potent for effector T helper cells, and less so for other
lymphocytes [3–6].B.V. This is an open access article u
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n),Early in the study of the immunosuppressive effects of CsA, it
was discovered that the drug had a strong suppressing effect on
the pathogenic immune responses of induced autoimmune dis-
eases in animals, such as rat experimental autoimmune en-
cephalomyelitis (EAE), an animal model of human multiple
sclerosis. However, paradoxically, its abrupt withdrawal tends to
cause a strong “rebound” of the immune response and an en-
hanced exacerbation of disease [7,8]. An explanation for this is
postulated to be that T cells inhibited by CsA undergo T cell pro-
liferation triggered by the lymphopenia that follows treatment [9].
However, the reason for the rebound effect and the activation
status of immune cells after CsA withdrawal has not been thor-
oughly studied.
We hypothesized that stimulatory signals received during T cell
suppression by CsA might accumulate and re-activate T cells after
CsA withdrawal, leading to hyperresponsiveness of T cells. There-
fore, in the case of CsA-suppressed interleukin (IL)-17 producing T
cell-mediated diseases such as multiple sclerosis (MS) or psoriasis,
the resumption of immune responses after CsA withdrawal may
therefore lead to a burst of IL-17 production that may be re-
sponsible for the relapse or exacerbation of disease. Based on this
hypothesis, we expect that relapse induced by CsA withdrawal
may be effectively blocked with antibodies to IL-17.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Ethics statement
Mice were kept under speciﬁc pathogen-free conditions, and
provided food and water ad libitum. Every effort was made to
minimize suffering during injections, and all surgery was per-
formed in humanely sacriﬁced mice. All animal experiments were
performed in accordance with the guidelines of the Bioscience
Committee of Hokkaido University and were approved by the
Animal Care and Use Committee of Hokkaido University (Approval
license No. 13–0131).
2.2. Induction of relapsing EAE
Female SJL/J mice (Charles River, Shizuoka, Japan), 8–10 weeks
old, were immunized with the encephalitogenic proteolipid pep-
tide (PLP)139-151 (sequence: HSLGKWLGHPDKF; purity490%)
emulsiﬁed in complete Freund's adjuvant (Difco, Detroit, MI) plus
Mycobacterium tuberculosis H37Ra (BD, Sparks, MD) (5 mg/ml).
Then, mice were immunized with 0.2 ml of the emulsion injected
subcutaneously into two locations at the tail root. At the time of
immunization and 48 h later, the mice were administered 400 ng
of pertussis toxin intravenously (List Biological Laboratories,
Campbell, CA). Signs and severity of disease were recorded be-
ginning on day 7 after immunization and continuing until day 50.
The following scale to measure disease severity was used: 0¼no
paralysis, 1¼ limp tail, 2¼ limp tail and weak gait, 3¼hind limb
paralysis, 4¼fore and hind limb paralysis, and 5¼moribund. Body
weight of mice was measured daily in addition to disease severity.
2.3. Treatment with CsA and antibody
Approximately 7–12 days after immunization, the ﬁrst episode
of clinical disease occurred in mice and lasted for 5–10 days. CsA
(Tokyo Chemical Industry, Tokyo, Japan) (125 mg/kg) was ad-
ministered intraperitoneally daily from day 8 to day 23 after PLP
peptide immunization. On days 24, 27, 30, 33 and 36 after im-
munization, the CsA-treated group was treated with anti-IL-17A
antibody (BZN035/Novartis, 10 mg/kg) or an isotype control anti-
body (mIgG2a, 10 mg/kg) intraperitoneally.
2.4. Measurement of cytokines
IL-6, TNF-α, IL-17A, IL-17F and IL-17A/F heterodimer con-
centrations in serum on day 30 or 40 after PLP peptide im-
munization were measured by IL-6 (BioLegend, San Diego, CA),
tumor necrosis factor-α (TNF-α; BioLegend), IL-17A (BioLegend),
IL-17F (eBioscience, Diego, CA) and IL-17A/F heterodimer (BioLe-
gend) enzyme-linked immunosorbent assay (ELISA) kits as speci-
ﬁed by the manufacturers.
2.5. Real-time PCR
Total RNA from mouse spleen and spinal cord at day 30 and 40
were extracted with TRIzol (Invitrogen, Waltham, MA) and ﬁrst-
strand cDNA was generated with ReverTra Ace (Toyobo, Osaka,
Japan). Real-time quantitative PCR was performed using KAPA
SYBR FAST qPCR Systems (KAPA Biosystems, Wilmington, MA). The
speciﬁc primers used were: 5′-TCCAGAAGGCCCTCAGACTA-3′
(sense for IL-17A) and 5′-AGCATCTTCTCGACCCTGAA-3′ (antisense
for IL-17A), 5′-CAAAACCAGGGCATTTCTGT-3′ (sense for IL-17F) and
5′-ATGGTGCTGTCTTCCTGACC-3′ (antisense for IL-17F), 5′-
CCAAACTGGATATAATCAGGAAAT-3′ (sense for IL-6) and 5′-
CTAGGTTTGCCGAGTAGATCTC-3′ (antisense for IL-6), 5′-ATGAG-
CACAGAAAGCATGATC-3′ (sense for TNF-α) and 5′-TCCACTTGGTGGTTTGCTACG-3′ (antisense for TNF-α), 5′-GACATTCATCATTGACC
TCGTG-3′ (sense for IL-21) and 5′-TCACAGGAAGGGCATTTAGC-3′
(antisense for IL-21), 5′-TCCCTACTAGGACTCAGCCAAC-3′ (sense for
IL-23) and 5′-AGAACTCAGGCTGGGCATC-3′ (antisense for IL-23),
5′-TGCATCTTGGCTTTGCAGCTCTTCCTCATG-3′ (sense for IFN-γ) and
5′-TGGACCTGTGGGTTGTTGACCTCAAACTTG-3′ (antisense for IFN-
γ), 5′-GCATGTAGAGGCCATCAAAGA-3′ (sense for GM-CSF) and 5′-
CGGGTCTGCACACATGTTA-3′ (antisense for GM-CSF), 5′-TGGACC
GCAACAACGGCATCTATGAGAAAACC-3′ (sense for TGF-β) and 5′-
TGGAGCTGAAGCAATAGTTGGTATCCAGGGCT-3′ (antisense for TGF-
β), 5′- TCAGGAGCCCACCAGTACA-3′ (sense for Foxp3) and 5′-
TCTGAAGGCAGAGTCAGGAGA-3′ (antisense for Foxp3), 5′-ACCA-
CAGTCCATGCCATCAC-3′ (sense for G3PDH) and 5′-TCCACCACCC
TGTTGCTGTA-3′ (antisense for G3PDH).
2.6. Isolation of CNS cells
Brains and spinal cords were homogenized and passed through
a 100 μm cell strainer and collected by centrifugation. Cells were
resuspended in 7 ml of RPMI 1640 medium, layered onto a Percoll
density gradient (GE Healthcare Life Sciences, Waukesha, WI,
USA), and centrifuged at 500 g for 30 min at room temperature.
Cells were isolated by collection of the interphase fraction be-
tween 30% and 70% Percoll. After washing in HBSS, cells were
analyzed by ﬂow cytometry.
2.7. Flow cytometry
In ﬂow cytometry, CD4-APC (BioLegend), IL-17-FITC (BioLe-
gend), and Foxp3-Alexa Fluor 488 (BioLegend) were used. Single-
cell suspensions obtained from spleen, brain, and spinal cords of
mice were incubated with anti-CD16/CD32 (BD Biosciences, San
Jose, CA, USA) to prevent Fc receptor binding and stained with
anti-CD4. Intracellular cytokine staining by CD4þ cells was ana-
lyzed by monitoring the expression of IL-17. Foxp3 staining was
performed according to the manufacturers’ protocol (BioLegend).
For intracellular cytokine staining, cells were stimulated with
50 ng/ml PMA plus 500 ng/ml ionomycin in the presence of 1 μl/
ml Brefeldin A (BioLegend) for 4 h. Samples were subjected to ﬂow
cytometric analyses using Gallios (BECKMAN COULTER). Data
analysis was performed with FlowJo v10 software (Tree Star Inc.,
Ashland, OR, USA).
2.8. Statistical analysis
Data are presented as means7SEM. Statistically signiﬁcant
differences between groups were calculated by Student's t-test.
Differences were considered to be signiﬁcant when Po0.05 (*) or
0.005 (**).3. Results
3.1. Induction of relapse in EAE mice after discontinuation of CsA
To establish a murine rebound model after CsA withdrawal, we
took advantage of the EAE model of multiple sclerosis because
relapse induced after CsA withdrawal was previously reported in
rats [7,8]. However, no reports of CsA-induced relapse in mice
have been reported. To establish CsA-induced relapse in mice, CsA
was injected into SJL/J mice immunized with PLP139-151 peptide
during their ﬁrst disease episode (from day 8 to day 23) (Fig. 1A).
In the CsA-treated group, EAE scores in the ﬁrst episode were re-
duced and a relapse was observed after day 40, compared to the
non-CsA-treated group (Fig. 1B). Thus, we successfully established
a murine rebound model induced by CsA withdrawal in PLP
Fig. 1. Establishment of a cyclosporin A-(CsA) induced EAE relapse model. (A) Protocol for CsA-induced EAE relapse model. Time points and dose of PLP peptide, pertussis
toxin and CsA are shown. (B) Clinical scores and weights of EAE mice with or without CsA at the indicated time points. Error bars indicate mean7SEM (n¼6 per group).
*Po0.05, **Po0.005. CFA, complete Freund's adjuvant; i.v., intravenous; i.p., intraperitoneally.
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3.2. Enhanced production of IL-17A after discontinuation of CsA
IL-17-producing T cells (Th17 and Tc17 cells) are key immune
cells for EAE development [10,11]. Among the IL-17 cytokine fa-
mily, Th17 cells express IL-17A and IL-17F [12], which bind to a
shared IL-17 receptor, IL-17RA/RC [13,14], suggesting that these
cytokines have similar biological functions. The IL-17A/F hetero-
dimer is also expressed in Th17 cells [15,16]. Therefore, we de-
termined whether IL-17A, IL-17F, or IL-17A/F heterodimer ex-
pressions were affected after CsA withdrawal. Serum, spleens and
spinal cord from EAE mice on days 30 and 40 were collected and
IL-17 levels were analyzed by ELISA for serum or by real-time PCR
for spleen and spinal cord (Fig. 2A). Enhanced IL-17A protein levels
were observed in serum on day 30 after discontinuation of CsA-
treatment compared to non-CsA-treatment, although there was no
such increase in IL-17F and IL-17A/F (Fig. 2B). Real-time PCR re-
vealed that IL-17A production was signiﬁcantly upregulated in
spleens on days 30 and 40 and tended to be increased in the spinal
cord on day 40 (P¼0.069) following CsA withdrawal (Fig. 2C).
There was no signiﬁcant difference in splenic IL-17F expressions
between CsA-treatment and non-treatment groups. However, IL-
17F expressions were downregulated in the spinal cord after CsA
withdrawal on day 30 (P¼0.022).
Next, we evaluated the percentage of Th17/Treg cells in spleen
and spinal cord by intracellular staining using ﬂow cytometry.
Although we observed increased proportion of splenic IL-17A-
producing cells in CsA-treatment mice, the population of IL-17A-
producing CD4þ T cells in spleen was not altered between CsA-
treatment and non-treatment groups (Fig. 2D). On the other hand,
the percentage of CD4þ Foxp3þ Treg cells in spleen was decreased
after discontinuation of CsA. In CNS-inﬁltrating lymphocytes, the
percentage and number of Th17 and Treg cells were not sig-
niﬁcantly altered by CsA treatment (Fig. 2D). These results suggest
that there were IL-17A-inducing immune cells besides Th17 cells
upon CsA withdrawal in EAE.
To determine whether IL-17A levels were selectively inducedby discontinuation of CsA in EAE, the levels of other proin-
ﬂammatory cytokines was evaluated by ELISA or real-time PCR. IL-
6 and TNF-α are important proinﬂammatory cytokines in the in-
duction of EAE and pathogenesis of MS [17–24]. Splenic IL-6 levels
at day 30 were upregulated by discontinuation of CsA, whereas IL-
6 levels in the serum and spinal cord were not signiﬁcantly dif-
ferent compared to controls (Fig. 3A and B). In contrast, the dis-
continuation of CsA signiﬁcantly reduced TNF-α levels in the ser-
um and spinal cord (Fig. 3A and B). To further investigate the
balance between Th17 and Treg cells by discontinuation of CsA, we
also examined mRNA expressions of other inﬂammatory/reg-
ulatory cytokines. We found that mRNA expression of IL-21, IL-23
and GM-CSF in the spleen on day 30 following CsA withdrawal
were upregulated, whereas we detected no signiﬁcant differences
in the expressions of IFN-γ mRNA between CsA-treatment and
non-CsA-treatment groups (Fig. S1). Moreover, Foxp3 mRNA ex-
pressions at day 30 were downregulated after CsA withdrawal in
both spleen and spinal cord. These data suggest that CsA with-
drawal induces the selective production of IL-17A and its related
genes systemically and locally.3.3. Anti-IL-17A antibody reduced severity of EAE relapse after CsA
treatment
To determine whether increased IL-17A levels are involved in
the augmented severity of EAE after CsA withdrawal, neutralizing
IL-17A antibodies were injected on day 24, 27, 30, 33, and 36 after
CsA withdrawal (Fig. 4A). Treatment with anti-IL-17A antibodies
effectively lowered the severity of relapse in EAE after CsA with-
drawal (P¼0.036 on day 38 and 39, P¼0.018 on day 40) (Fig. 4B).
We also noted that clinical EAE score was elevated on day 43. Since
the elevation occurred 7 days after the ﬁnal anti-IL-17A antibody
treatment, it may be due to insufﬁcient level of anti-IL-17A anti-
body for neutralizing recurred IL-17A production. Therefore, the
data suggest that the upregulation of IL-17A production upon CsA
withdrawal is involved in EAE relapse.
Fig. 2. Expression of IL-17 after discontinuation of cyclosporin A (CsA). (A) Protocol for sampling of serum, spleen and spinal cord after discontinuation of CsA. (B) Levels of
IL-17A, IL-17F, or IL-17A/F heterodimer in serum. Serum on day 30 or 40 was collected and used for IL-17A, IL-17F, or IL-17A/F heterodimer measurement by ELISA in triplicate
wells and is shown as the mean7SEM. (C) Analysis of gene expression of IL-17A or IL-17F in spleen or spinal cord on days 30 or 40. Total RNA extracted from the spleen or
spinal cord of individual mice on days 30 or 40 was subjected to quantitative real-time PCR. Expression levels are normalized to G3PDH. (D) At day 30 of EAE, spleen cells and
CNS inﬁltrating cells were evaluated for secretion of IL-17 and for expression of Foxp3 by CD4þ cells. Error bars represent mean7SEM (B–C, n¼6; D, n¼5–7 per group).
*Po0.05. CFA, complete Freund's adjuvant; i.v., intravenous; i.p., intraperitoneally.
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CsA is commonly used in current medical practice as an ef-
fective treatment for autoimmune diseases. Although its effec-
tiveness is sustainable with continued treatment, the use of the
drug in many patients is associated with side effects such as hy-
pertension and renal damage that limit the length of time that it
can be used. Therefore, most patients stop using the drug within
2 years in the US [1]. Cyclosporine is a strong immunosuppressant
and deteriorates immunocompromized conditions, thereby in-
creasing the risk of complications by serious infections. Therefore,
as a general rule, when switching to biologics which attenuate
immunoreactions, complete withdrawal of cyclosporine before
switching is recommended [25]. However it is generally true that
the direct switch to biologics causes the relapse of symptoms
when the biologic therapy takes time to be effective. Therefore, the
transition from CsA to a subsequent therapeutic can be difﬁcult to
manage for both physicians and patients. A therapeutic switching
methodology that can be accomplished with a lower risk of ex-
acerbation during the transition period would be of great beneﬁt
to autoimmune patients.EAE is an animal model of human multiple sclerosis caused by
inﬂammation of the central nervous system in mice and rats im-
munized with encephalitogenic peptides such as PLP or MOG
peptide [26]. In this study, CsA treatment and its discontinuation
induced EAE relapse in mice indicating EAE to be a suitable model
for studying CsA withdrawal-dependent rebound including re-
lapse or exacerbation of disease. IL-17 deﬁcient mice or treatment
with neutralizing anti-IL-17A antibody inhibited the severity of
EAE disease scores, suggesting IL-17A is a critical cytokine for the
development of EAE [10,27,28]. Therefore, we measured IL-17 le-
vels in a CsA withdrawal-dependent rebound model on days 30
and 40, the time points after CsA treatment and before relapse,
respectively. IL-17A levels were increased locally and systemically
in EAE mice after CsA withdrawal.
IL-17A and IL-17F are highly homologous members of the IL-17
family [29,30] and are a common ligand for IL-17RA/RC [13,14].
Previous studies reported that IL-17A and IL-17F are produced by
Th17 cells [12] and are both regulated by cytokines such as IL-23,
IL-6 and transforming growth factor (TGF)-β as well as transcrip-
tion factors such as RAR-related orphan receptor-γT (ROR-γT) and
signal transducer and activator of transcription 3 (STAT3) [27,31–
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Fig. 3. Expression of IL-6 and TNF-α after discontinuation of cyclosporin A (CsA). (A) Expression of IL-6 and TNF-α in serum on days 30 or 40 by ELISA in triplicate wells are
shown as the mean7SEM. (B) Analysis of IL-6 and TNF-α gene expression in the spleen or spinal cord on days 30 or 40 by quantitative real-time PCR. Expression levels are
normalized to G3PDH. Error bars indicate the mean7SEM (n¼6 per group). *Po0.05, **Po0.005.
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monstrated that CsA withdrawal induced the selective local and
systemic production of IL-17A and blockade with neutralizing IL-
17A antibodies protected mice from EAE relapse caused by CsA
withdrawal. This suggested that IL-17A is a key cytokine that
mediates disease rebound after CsA treatment. These results are
consistent with a previous study demonstrating that IL-17A and IL-
17F have a differential role in autoimmune diseases, although they
are important for host defence against pathogenic bacteria [34]. IL-
17A is critical for the development of autoimmune diseases in-
cluding collagen-induced arthritis and EAE, whereas IL-17F is less
important. However, the signals involved in selective IL-17A pro-
duction after CsA withdrawal is unknown. Possible explanations
for selective IL-17A production might be the resumption of Th17
cells after CsAwithdrawal accompanied by hyperresponsiveness to
stimulation because of accumulated stimulatory signals received
while T cells were suppressed by CsA. In EAE, T cells receive Th17-
favoring stimulatory signals such as IL-6 and TGF-β that are in-
volved in Th17 cell differentiation. Although both IL-17A and IL-
17F are produced by Th17 cells, the production of IL-17A is much
higher than IL-17F [35], suggesting the greater involvement of IL-
17A production by T cells in the CsA withdrawal-dependent re-
bound effect.
IL-6 and TNF-α are important cytokines for the development of
EAE. Upon CsA withdrawal, IL-6 expression was increased in the
spleen, but not in the spinal cord. Inﬂammation in the spinal cord,
the target tissue in EAE, was related to the severity of EAE. No
change in IL-6 levels in the spinal cord suggests that IL-6-ex-
pressing T cells do not inﬁltrate into the spinal cord. TNF-α levelswere signiﬁcantly decreased after CsA withdrawal, suggesting that
CsA may facilitate the sustained inhibition of TNF-α production
from T cells and that anti-TNF-α antibody treatment is not a
candidate for rebound after CsA withdrawal. Augmented IL-17A
production in the spinal cord and spleen at day 40 indicated that
IL-17A-producing T cells inﬁltrate into the spinal cord just before
relapse. Taken together with the cytokine analysis, T cells produ-
cing IL-17A might be critical for EAE relapse after CsA withdrawal.
We also found that the population of IL-17A-producing CD4þ T
cells was not changed after CsA withdrawal. This result suggests
that IL-17A may be produced by different kind of immune cells
including CD8þ T cells and γδT cells. Further studies are needed to
elucidate the cellular and molecular mechanisms after CsA
withdrawal.
In summary, we report the establishment of a murine rebound
EAE model induced by CsA withdrawal, the enhanced production
of IL-17A after CsA withdrawal, and reduction of disease rebound
by neutralizing anti-IL-17A antibodies. Therefore, neutralizing
anti-IL-17A antibodies might be a potential switching drug after
CsA therapy.Conﬂict of interest
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Fig. 4. Anti-IL-17A antibody reduces severity of the EAE relapse after the discontinuation of cyclosporin A (CsA). (A) Time point and dose of PLP peptide, pertussis toxin, CsA,
and anti-IL-17A or control antibody. (B) Clinical scores of EAE mice treated with neutralizing anti-IL-17A or control antibody after discontinuation of CsA at the indicated time
points. Error bars indicate the mean7SEM (n¼7/anti-IL-17A antibody group, n¼8/control antibody group). *Po0.05. CFA, complete Freund's adjuvant; i.v., intravenous; i.p.,
intraperitoneally.
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